Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-577-6 | CAS number: 97-39-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Neurotoxicity
Administrative data
Description of key information
Because 1,3-di-o-tolylguanidine is preferentially stored in the sigma-receptors in the brain, in particular in the brain stem, it is widely used in neuropharmacology as a model coumpound for studying disturbances in behaviour and movement (BG Chemie, 1999).
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Link to relevant study records
- Endpoint:
- neurotoxicity
- Remarks:
- acute
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment.
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- A Forced Swimming (Porsolt's test) and a Open field test were performed on rats.
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: no data
- Age at study initiation: no data
- Weight at study initiation: 250-300 g
- Fasting period before study: no data
- Housing: 6 per cage
- Diet (e.g. ad libitum): free access
- Water (e.g. ad libitum): free access
- Acclimation period: no data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/-2°C
- Humidity (%): no data
- Air changes (per hr): no data - Route of administration:
- intraperitoneal
- Vehicle:
- other: 1% aqueous solution of tween 80
- Details on exposure:
- Administration volume = 2 ml/kg
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 3 injections
- Frequency of treatment:
- 3 injections
- Remarks:
- Doses / Concentrations:
2.5 and 5 mg/kg
Basis:
nominal conc. - No. of animals per sex per dose:
- Forced swimming test : 8 rats/ group
Open field test: 6 rats/group - Control animals:
- not specified
- Details on study design:
- Forced swimming (Porsolt's) test
The animals were subjected to two trials during which they were forced to swim in a cylinder (40 cm high, 18 cm in diameter) filled with water (23-25°C) to a height of 15 cm. There was a 24-hour interval between the first and second trial; the first trial lasted 15 min, the second 5 min. The total duration (s) of immobility was measured throughout the second trial. DTG (2.5 and 5 mg/kg) was given separately or in combination with MEM (2.5 mg/kg) three times: at 24, 5, and 1 h before the test.
Open field test
The center of an open platform (divided into sectors, without walls) was illuminated with a 75 W bulb, hung directly 75 cm above it. During all experiments the rest of the laboratory room was dark. To start the test, animals were placed gently in the center of the platform and were allowed to explore it freely. Ambulation (the number of crossings of sector lines), peeping (the number of times the animals peeped down from the edge of the arena) or rearing and the time of walking were recorded directly for 5 min. Drug treatments were carried out according to the same experimental schedule as described above (three injections). - Statistics:
- The data were evaluated by two-way ANOVA, followed, when appropriate, by individual com¬parisons with the control using Dunnett's test.
- Details on results:
- DTG (2.5 or 5 mg/kg) did not change the immobility time of rats. Co-administration of DTG with MEM induced antidepressant-like effect in Porsolt's test (at both dose used of DTG). These synergistic effects were not an expression of a general change in locomotor activity, since it was unaltered after co-administration of both sigma receptor ligands and MEM.
The antidepressant-like effect of DTG at a dose of 5 mg/kg, given jointly with MEM, was antagonized by progesterone (20 mg/kg). - Conclusions:
- DTG (2.5 or 5 mg/kg) did not change the immobility time of rats.
- Executive summary:
The obtained results show that DTG, the sigma1 and sigma2 receptor agonist, exerts a synergistic effect with memantine, an uncompetitive NMDA receptor antagonist, in the forced swimming test in rats, and that progesterone and BD 1047, the sigma1 receptor antagonists, counteract this effect. The results suggest that the sigma1receptor subtype may contrebute to the behavioral response induced by combined administration of DTG and memantine in Porsolt's test in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 30 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The majority are acute studies performed on rats. These studies are reliable with a klimisch score of 2.
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Several studies had analyzed the effect on DOTG on central nervous system.
Summary of specific studies :
DOTG is a compound hightly selective sigma receptor ligand; DTG has reported to bind for both the sigma1 and sigma2 receptor subtypes as an agonist (Nakazawa 1999). Results of study suggest that the receptors on which DTG acts are located on the mossy fiber terminals in the CA3 region and are absent in the CA1 region (Debonnel 1996).
DTG demontrated full concentration-dependent neuroprotection with a EC50 (neuroprotection) at 42.7 µM (DeCoster 1995).
DTG antagonize the apomorphine-induced aggression and climbing, but not affect the apomorphine stereotypy (Maj 1993).
DTG acts as a typical neuroleptic (antagonizes the apomorphine-induced aggression and climbing) and at the same time, as dopamine stimulants (antagonize neuroleptic-induced catalepsy). When given alone it exhibits no visible behavioural effects (Maj 1996).
DTG elicits a marked deviation of the head (torticollis) following microinjection into the red nucleus. An acute abnormal postural change (dystonia) was observed 1-5 min after injection of DOTG (Faherty 1997, Nakagawa 1999).
DOTG produces hypothermia in the rodent after s.c. and i.c.v. administrations (Bejanian 1991). This findings represents a potential confound of effects in nociceptive assays that use reactivity to thermal stimuli as an end point.
Consistent with a sigma receptor site of action, DOTG antinociception in the aforementioned study was blocked in a dose-dependent manner by rimcazole, a selective sigma receptor ligand and putative antagonist.
In the formalin test, DTG produced no visible signs of motor dysfunction or malaise alone or in combinaison with rimcazole.
DTG produced antinociception on the acute phase of the formalin test following systemic administration (Kest (b) 1995). The formalin test of nociception, in which a dilute volume of formaldehyde is injected subcutaneously is one model of tonic pain.
DTG (2.5 or 5 mg/kg) did not change the immobility time of rats (Skuza 2003).
Justification for selection of effect on neurotoxicity via oral
route endpoint:
Several studies had analyzed the effect on DOTG on central nervous
system.
Justification for classification or non-classification
No classification is justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
